Introduction
Keratinocytes have been demonstrated to produce a wide range of cytokines and growth factors, including IL-1, IL-3, IL-6, IL-8, IL-1O, colony-stimulating factors, TNF,, TGFa, TGF,,, fibroblast growth factor, IL-1 receptor antagonist, and amphiregulin (reviewed in reference 1). These cytokines are thought to play an important role in mediating inflammatory and proliferative processes in the skin. To date the epidermis has not been considered a source of PDGF in man. In the present study we examined the possibility that normal human keratinocytes and normal epidermis are able to synthesize and secrete PDGF.
PDGF is the principle mitogen in serum for cultured cells of mesenchymal origin, including fibroblasts, and smooth muscle cells (reviewed in reference 2). PDGF is a disulfidelinked dimer of two chains termed A chain and B chain, which can form dimers of PDGF-AA, PDGF-AB, and PDGF-BB. All three of the dimer forms have been identified from natural sources and shown to be biologically active (3, 4) . The A and B chains share -60% amino acid sequence identity, including eight conserved cysteine residues in the mature coding sequence. The biological activities of PDGF are mediated via binding to cell-surface receptors. Two PDGF receptors have been identified, termed alpha and beta (5, 6) . The genes for the two receptors code for transmembrane proteins which contain split tyrosine kinase domains within the cytoplasmic portion of the molecules (7-1 1 ). Similar to the PDGF ligands, dimerization ofthe two receptors is thought to be required forthe generation of high affinity binding sites. Receptor dimerization appears to be mediated through ligand binding such that the isoform of PDGF presented to the cell will determine the types of receptor dimers formed (12, 13) . The three potential PDGF receptor dimers have different ligand binding specificities for the three forms of PDGF with alpha/alpha dimers binding PDGF-AA, AB, and BB, alpha/beta dimers binding PDGF-AB, BB and beta/beta dimers binding only PDGF-BB (reviewed in reference 14) .
Due to the various biological activities stimulated by PDGF on cells in culture, PDGF has been implicated as one of the primary components involved in stimulating dermal wound repair. In addition to its mitogenic activities, PDGF is a chemoattractant for fibroblasts ( 15 ) , and monocytes and neutrophils ( 16) . PDGF has also been shown to stimulate increased levels of extracellular matrix production by fibroblasts in culture ( 17 ) . Recent studies have shown that the topical application of PDGF-BB to wounds made on diabetic mice, which have impaired wound healing capabilities, stimulates both accelerated wound closure and the development of thickened granulation tissue ( 18). PDGF-BB treatment has also been recently shown to accelerate the rate ofwound healing in humans when added to chronic pressure ulcers ( 19) .
Platelets and macrophages have been described as two of the principle sources ofPDGF at the site ofa cutaneous wound. In this manuscript we describe the expression of PDGF A and B chain mRNA and protein in cultured human keratinocytes. We additionally show that PDGF is produced in normal human epidermis as well as at sites of acute tissue repair in wounded skin. These results demonstrate that the epidermis of human skin is a third major source of PDGF for cutaneous wound healing. This also suggests that the epidermis may play a direct role in dermal repair processes by the production of PDGF and its subsequent actions on target cells within the dermis.
Methods
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Growthfactors, antibodies, and cultured cells. PDGF AA and BB were generated in a yeast expression system and purified to homogeneity as previously described (20) . Protein concentrations were determined by amino acid analysis. IL-la and TGF,, were purchased from Genzyme Corp. (Cambridge, MA) and a gift ofDr. Bruce Magan (Department of Cell Biology and Anatomy, Oregon Health Sciences University, Portland, OR), respectively.
Anti-PDGF monoclonal antibodies were generated and characterized as previously described (3). The ligand binding specificity for the anti-PDGF monoclonal antibodies are as follows: 127.222 (PDGF-AA), 127.822 (PDGF-AA), 127.573 (PDGF-AA and AB), 120.121 (PDGF-BB), 120.311 (PDGF-BB), 172.511 (PDGF-BB), 121.611 (PDGF-BB and AB). Rabbit anti-PDGF A chain IgG and rabbit anti-PDGF B chain IgG polyclonal antibodies used in the ELISAs and as neutralizing antibodies in the mitogenesis assay (described below) were generated as previously described (3) by immunizing rabbits with purified recombinant PDGF-AA or PDGF-BB, respectively. The monoclonal antibodies and the rabbit anti-PDGF IgG antibodies were isolated by protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) chromatography. Affinity-purified rabbit anti-PDGF A chain and affinity-purified rabbit anti-PDGF B chain polyclonal antibodies, used for immunostaining of human tissue, were isolated by passage of the serum over a Sepharose4B column coupled with either PDGF-AA or PDGF-BB. The bound antibody was eluted with 0.1 M citrate, pH 3.0, then the isolated antibody cross-adsorbed on the opposite ligand column to remove any antibody cross-reacting with both PDGF A and B chain. The affinity isolated rabbit anti-PDGF A chain and B chain antibodies recognize PDGF-AA and AB, and BB and AB, respectively, with < 1% cross-reactivity to the opposite homodimer. PDGF-AA and BB were coupled to CnBr-activated Sepharose-4B (Pharmacia Fine Chemicals) as described by the manufacturers at a ratio of 5 mg/g of dry gel.
The generation and characterization ofanti-PDGF receptor monoclonal antibodies PR7212 (beta receptor) and PR292 (alpha receptor) have been previously described (21, 22) . Monoclonal antibody 169.522 was produced by fusing NS-l myeloma cells with spleen cells isolated from mice immunized with chimeric PDGF receptor molecules containing the extracellular domain of the human PDGF alpha receptor and the constant domains of human immunoglobulin heavy and light chains (Hart, C. E., and D. Gilbertson, unpublished data). This antibody, which specifically recognizes the extracellular domain of the PDGF alpha receptor, was characterized for receptor binding specificity by the same criteria as used for antibodies PR7212 and PR292 (21, 22 To obtain detergent solubilized cell extracts, cells were washed with PBS, then extracted with RIP buffer (20 mM Tris-HCl, pH. 8.0, 100 mM NaCl, I mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate, 10 mM Nal, 1% BSA) on ice. The extract was centrifuged at 2,000 g to pellet cellular debris, and the supernatant was harvested.
Northern blot analysis. Cytoplasmic mRNA was isolated using the NP-40 lysis method as described by Mushinski et al. (23) . Poly A' RNA was obtained by two passages over oligo dT cellulose (Boehringer Mannheim, Indianapolis, IN). RNA samples (2 jg/lane) were electrophoresed on a I% agarose-formaldehyde gel, transferred to nitrocellulose, and hybridized with 32P-labeled cDNA-probes. The PDGF A chain probe was a 1.3-kb EcoRI fragment that corresponds to the short version of the PDGF-A mRNA (24) and which was agift from Christer Betsholtz (Uppsala University, Uppsala, Sweden). The B chain probe used was a PstI/XbaI 1.0-kb fragment which codes for the v-sis sequence (25) and which was a gift from Keith Robbins (National Institutes of Health, Bethesda, MD). The PDGF alpha receptor probe contains nearly the entire coding sequence and corresponds to bp 252 -) 3978 (11). The PDGF beta receptor probe contains the full length human cDNA and corresponds to bp 356 5570 (8) . DNA probes were radiolabeled using the random hexamer method (26) .
Immunostaining of normal human skin for PDGF. Cryostat sections of normal human skin were prepared on gelatin-coated slides and were postfixed with 10% buffered formalin for 10 min. Sections were reacted with monoclonal antibodies 120.311, 127.822, 120.121, and 127.573, using 0.25-1.0 ,ug/ml final concentrations. All antibodies, including those used for competition with purified antigen, were diluted in PBS containing 10 mg/ml BSA. Staining by 127.573 was competed by the addition of 1 jg of purified PDGF-AA. No competition for 127.573 staining was observed with 10 ,ug/ml PDGF-BB. Staining by 120.121 was competed by 10 ug/ml BB. Antibody binding was visualized using an anti-mouse avidin-biotin complex kit (Vector Laboratories, Burlingame, CA) and 3-amino-9-ethyl-carbozol as the chromagen.
Immunostaining of human wounds for PDGF. Wounds were cre- (Fig. 1) . Only trace levels of B chain mRNA were detected in the KBM-cultured cells. The addition of IL-Ia (10 ng/ml) to the culture media for 12 h resulted in an increase in a 4.0-kb transcript for PDGF B chain with no corresponding increase in the level ofA chain mRNA.
In contrast, an increase in the levels of both A chain and B chain mRNA were detected after the addition of TGF,, (10 ng/ml) to the cells for 12 h.
Production of PDGF-AA, AB, and BB polypeptide. To monitor the production of PDGF polypeptide by human keratinocytes, 24 -h conditioned culture media was analyzed by ELISA for the presence of the three isoforms of PDGF (AA, AB, BB). The individual PDGF isoforms were detected and quantitated as previously described (3) using isoform-specific monoclonal antibodies as the catching antibodies in sandwich ELISA formats. Only PDGF-AA was detected in the conditioned culture media of cells grown in KBM (Table I) (Fig. 2) . Addition of rabbit anti-PDGF B chain had no inhibitory effect on either the keratinocyte culture media or on purified PDGF-AA. These results demonstrate that PDGF-AA present in keratinocyte-conditioned culture media is mitogenically active. They also support the findings that there are no significant levels ofPDGF-AB or BB in the keratinocyte media, due to the lack of inhibitory activity by the rabbit anti-PDGF B chain antibody. Analysis ofPDGF receptor expression in keratinocytes. To determine if PDGF might be functioning in an autocrine fashion in human keratinocytes, we monitored for the presence of PDGF receptors in these cells. Direct cell-surface expression studies were done with monoclonal antibodies PR292 and PR72 12. These antibodies recognize extracellular epitopes on the PDGF alpha and beta receptors, respectively. The binding of these antibodies was monitored on both keratinocytes and human dermal fibroblasts. To demonstrate binding specificity ofthe antibodies to the PDGF receptors, the test cells were first incubated at 37°C with 50 ng/ml of PDGF-BB for increasing lengths of time to stimulate receptor downregulation. Treat (Fig. 4) . Equal loading of mRNA in all lanes of the Northern blot was confirmed by ethidium bromide staining and actin mRNA determinations (data not shown). The lack of PDGF receptor expression by cultured keratinocytes was further confirmed by PCR analysis (data not shown).
Immunostaining ofPDGF in human skin. To determine if keratinocytes express PDGF in vivo, cryosections of normal human skin were stained with monoclonal antibodies specific for the A and B chains of PDGF. Staining ofthe epidermis was observed with monoclonal antibody 127.573, which is directed against the PDGF-A chain and detects both PDGF-AA and AB. Staining was present from the basal layer into the granular layer (Fig. 5 A) but was not ob-served in the cornified layer. This staining was abolished when the antibody was first pread- sorbed with PDGF-AA (Fig. 5 B) but not with PDGF-BB (data not shown). A second monoclonal antibody, 127.822, which only recognizes PDGF-AA, showed a similar staining pattern (Fig. 5 C) . The presence of PDGF BB in the epidermis was demonstrated by the staining observed with monoclonal antibody 120.121, which specifically detects PDGF-BB. Staining with this antibody was similarly observed from the basal layer into the granular layer (Fig. 5 D) , and was blocked for by preadsorption of the antibody with PDGF-BB (Fig. 5 E) , but not with PDGF-AA (data not shown). A second monoclonal antibody specific for PDGF-BB, 120.31 1, demonstrated a similar staining pattern (Fig. 5 F) . Thus, both PDGF-AA and BB are present in normal human epidermis. However, the presence of PDGF-AB cannot be evaluated by the antibodies used in this study.
To assess the expression of PDGF in human skin at the site of acute healing wounds, we obtained biopsies of partial thickness incised wounds made with a Simplate II bleeding time device (28) . 1-d-old wounds were analyzed for the presence of PDGF by immunostaining using affinity-purified rabbit anti-PDGF A chain and anti-PDGF B chain polyclonal antibodies. PDGF A chain was clearly detected in the epidermis adjacent to and away from the wound site in l-d wounds (Fig. 6 A) as well as in the newly reconstituted normal epidermis in older wounds (data not shown). Similar findings were observed with PDGF B chain staining, though the intensity of the staining was greatly reduced from that obtained with the anti-PDGF A chain antibody (Fig. 6 B) . During the course ofwound maturation (days [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] ) there was no detectable upregulation ofstaining for either PDGF A chain or B chain in the epidermis.
There was a striking difference for the staining ofthe provisional wound matrix of l-d wounds by the two antibodies. Strong staining was observed with the anti-PDGF A chain antibody (Fig. 6 A) while essentially no staining was observed with the anti-PDGF B chain antibody (Fig. 6 B) . As the wounds matured (days 4-21) there was a continual decrease in the staining for PDGF-A chain as the provisional wound matrix was replaced by granulation tissue. During this same period there was no significant change in staining for PDGF-B chain in the dermis (data not shown).
Immunostaining ofPDGF receptor in human skin. PDGF receptor expression in human skin was monitored by immuno-A t1 Figure 5 . PDGF expression in normal human skin. PDGF-A and PDGF-B peptide expression in normal human skin was determined by immunohistochemistry using PDGF isoform specific monoclonal antibodies. mAbs 127.573 b and 120.121 were coincubated with purified PDGF-AA and BB, respectively, to demonstrate antibody binding specificity. also be a major source of PDGF for wound healing in the skin. The identification of PDGF by immunostaining in both nonwounded and in regenerating epithelium strongly support this hypothesis. The source of the PDGF A chain observed by immunostaining in the provisional wound matrix is not clear. However, the detection of only PDGF-AA in the conditioned media of cultured keratinocytes and the presence of mainly PDGF A chain in the provisional wound matrix suggests that the A chain present may be derived from the epidermal cells. This idea is further supported by the knowledge that PDGF present in the alpha granules ofhuman platelets is composed of approximately equal amounts of both PDGF A and B chains (3). Additionally, it has been shown that macrophages in culture express both PDGF A and B chain polypeptide (32) . These data support the role of keratinocyte-derived PDGF in cutaneous wound healing.
The finding of constitutive expression of PDGF polypeptide in epidermal cells of both nonwounded and wounded human tissue is in contrast to the findings of Antoniades and co-workers (33) who only detected transient expression of PDGF B chain in the epidermis between I and 4 d after placement of full-thickness wounds in pigs. It is unclear if this discrepancy is due to differences in the detection methods for PDGF or represents a real biologic difference between human and porcine epidermis.
The production ofPDGF by human keratinocytes does not appear to function as an autocrine factor in epidermal repair. Neither PDGF receptor polypeptide nor mRNA was detected in cultured human keratinocytes. Additionally, neither PDGF alpha or beta receptor was detected by immunostaining in the epidermis of either normal skin, or in the epidermis of healing human wounds ranging from 1 to 21 d in age. It has recently been reported by Antoniades and co-workers (33) that there is transient expression, as measured by both in situ hybridization and immunostaining, of PDGF beta receptor in the epidermis of porcine wounds. Again, whether this reflects variation between species or simply differences in detection methods from those reported here is unclear. The identification of functional PDGF receptors has not yet been described in cultured porcine keratinocytes.
Using a panel of monoclonal antibodies to the PDGF receptors we have identified a subset of antibodies which immunostain human keratinocytes both in culture and in skin biopsies. One of the antibodies to the PDGF beta receptor appears to detect a 200-kD cytoplasmic molecule as demonstrated by immunoprecipitation of [35S]methionine labeled cell extracts (data not shown). The finding that this molecule is expressed cytoplasmically, and that its presence is not modified after the addition of either PDGF-AA or BB to cultured keratinocytes (data not shown) suggests that it is not a functional PDGF receptor but that it shares similar antigenic determinants with the PDGF beta receptor. It is possible that the staining observed by Antoniades and co-workers could have been to a similar molecule in porcine keratinocytes.
The detection of only PDGF-AA in the culture media of keratinocytes, although the cells make both PDGF A and B chain mRNA, is consistent with previous findings where only PDGF-AA is efficiently secreted by many cell types (34-36). The PDGF-AA detected in the culture media corresponds in size by Western blot to the short form of A chain (data not shown). The mRNA coding for the short form lacks exon 6, which is present in the long form of A chain and which codes for a stretch ofbasic amino acid residues. This stretch ofamino acids appears to act as a heparin-binding retention sequence to maintain cell association of the long form of PDGF-AA (35, 36) . A similar stretch of basic residues is found in the B chain of PDGF (34, 35). While only PDGF-AA was detected in the culture media, all three PDGF isoforms (AA, BB, and AB) were detected in cell extracts. It is interesting to note that elevated levels of B chain mRNA detected in the IL-la-and TGF,O-treated cells did not correspond to substantial increases in the production of PDGF B chain protein. Additionally, the PDGF B chain produced appears to be primarily directed into PDGF-AB.
The recent identification that human keratinocytes are a rich source of a wide variety of growth factors necessitates reevaluation ofthe potential roles played by these cells in cutaneous inflammation and wound healing. In addition to providing a boundary layer for prevention of water loss, and protection against surface abrasion, we now must view keratinocytes as a major source of cytokines which will directly influence adjacent dermal constituents. While we have primarily focused on the potential role of keratinocyte-derived PDGF in acute wound repair in this manuscript, one could speculate for a much broader role for PDGF in skin function. Not only through direct actions on cells within the dermis, but indirectly on the epidermis through the regulation ofvascular growth and the subsequent availability of the necessary nutrients.
